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Abstract
Blocking oncogenic signaling induced by the BRAFV600E mutation is a promising approach for melanoma treatment. We 
tested the anti-tumor effects of a specific inhibitor of Raf protein kinases, PLX4032/RG7204, in melanoma cell lines. 
PLX4032 decreased signaling through the MAPK pathway only in cell lines with the BRAFV600E mutation. Seven out of 10 
BRAFV600E mutant cell lines displayed sensitivity based on cell viability assays and three were resistant at concentrations 
up to 10 μM. Among the sensitive cell lines, four were highly sensitive with IC50 values below 1 μM, and three were 
moderately sensitive with IC50 values between 1 and 10 μM. There was evidence of MAPK pathway inhibition and cell 
cycle arrest in both sensitive and resistant cell lines. Genomic analysis by sequencing, genotyping of close to 400 
oncogeninc mutations by mass spectrometry, and SNP arrays demonstrated no major differences in BRAF locus 
amplification or in other oncogenic events between sensitive and resistant cell lines. However, metabolic tracer uptake 
studies demonstrated that sensitive cell lines had a more profound inhibition of FDG uptake upon exposure to 
PLX4032 than resistant cell lines. In conclusion, BRAFV600E mutant melanoma cell lines displayed a range of sensitivities 
to PLX4032 and metabolic imaging using PET probes can be used to assess sensitivity.
Background
Improved knowledge of the oncogenic events in mela-
noma indicates that a majority of mutations activate the
mitogen-activated protein kinase (MAPK) pathway [1,2].
The most frequent mutation in the MAPK pathway is in
the BRAF gene, present in 60-70% of malignant melano-
mas [3]. NRAS mutations occur in approximately 15% of
melanomas [1,4,5] and are mutually exclusive with BRAF
mutations [6,7]. The majority of mutations in BRAF are
accounted for by a single nucleotide transversion from
thymidine to adenosine leading to a substitution of valine
by glutamic acid at position 600 (termed BRAFV600E)
[3,4,8], which leads to a 500-fold increase in activity com-
pared to the wild type protein kinase [8].
PLX4032 (also known as RG7204) was developed as a
specific inhibitor of Raf. It is an analogue of the pre-clini-
cally tested PLX4720 [9]. PLX4720 inhibits the mutated
B-Raf kinase at 13 nM, while the wild type kinase requires
tenfold higher concentration (160 nM) [9], thus predict-
ing high specificity for BRAFV600E mutant cell lines. The
basis of this specificity for the mutated kinase is thought
to be the preferential inhibition of the active conforma-
tion of B-Raf. In addition, its access to a Raf-selective
pocket accounts for the selectivity against most other
non-Raf kinases, which require concentrations 100 to
1000 times higher for kinase inhibition. The only excep-
tion is the breast tumor kinase (BRK), which is inhibited
at 130 nM, a one-log difference compared to the V600E
mutated B-Raf kinase [9].
In the current studies we analyzed a panel of human
melanoma cell lines with defined oncogenic alterations
for sensitivity to PLX4032. In addition, with a view to
development of a biomarker to indicate response to tar-
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geted therapy, we investigated a non-invasive method of
imaging resistance versus sensitivity in vivo. We describe
that PLX4032 works differentially in melanoma cell lines
with BRAFV600E mutations and that the positron emission
tomography (PET) tracer 2-fluoro-2-deoxy-D-glucose
(FDG) can be used in non-invasive PET imaging to dis-
tinguish between sensitive and resistant cell lines.
Materials and methods
Reagents and cell lines
PLX4032 (also known as RG7204 or RO5185426) was
obtained under a materials transfer agreement (MTA)
with Plexxikon (Berkeley, CA) and dissolved in DMSO
(Fisher Scientific, Morristown, NJ) to a stock concentra-
tion of 10 mM. SKMEL28 was obtained from American
Type Culture Collection (ATCC, Rockville, MD), and the
remaining human melanoma cell lines (M series) were
established from patient's biopsies under UCLA IRB
approval #02-08-067. Cells were cultured in RPMI 1640
with L-glutamine (Mediatech Inc., Manassas, VA) con-
taining 10% (unless noted, all percentages represent vol-
ume to volume) fetal bovine serum (FBS, Omega
Scientific, Tarzana, CA) and 1% penicillin, streptomycin,
and amphotericin (Omega Scientific). All cell lines were
mycoplasma free when periodically tested using a Myco-
alert assay (Lonza, Rockland, ME).
BRAFV600E mutation analysis
Genomic DNA was extracted using FlexiGene DNA Kit
(Qiagen, Valencia, CA) and the 200 bp region flanking the
mutation site was amplified by PCR using Invitrogen
online primer design (Invitrogen, Calsbad, CA) as
described [10]. The PCR products were purified using
QIAquick PCR Purification Kit (Qiagen), sequenced
(Laragen Inc., Los Angeles, CA) and aligned with the
BRAF gene (http://www.ncbi.nlm.nih.gov, accession no.
NT_007914).
Oncomap 3 core mass-spectrometric genotyping
Samples were run through OncoMap 3 which interro-
gates 396 somatic mutations across 33 genes. Whole
genome amplified DNA at 5 ng/μl was used as input for
multiplex PCR as described previously [11]. Single-base-
pair primer extension (iPLEX) was performed in a 2 μl
reaction volume using iPLEX Gold single base extension
enzyme (Sequenom, San Diego, CA). Products were res-
ined and transferred to SpectroCHIPs for analysis by
MALDI-TOF mass spectrometry [11]. All mutations
were confirmed by direct sequencing of the relevant gene
fragment.
SNP array analysis
DNA extracted from the full panel of 13 human mela-
noma cell lines was hybridized onto Illumina Beadchip
Human Exon 510S-Duo (Illumina Inc., San Diego, CA).
DNA copy number was calculated using PennCNV (*) as
described [12]. Eight of the cell lines (M202, M207, M229,
M249, M255, M257, M263, M308) were additionally ana-
lyzed using Affymetrix GeneChip® Human Mapping 250K
Nsp Array (Affymetrix, Santa Clara, CA).
Cell proliferation and viability assays
Melanoma cell lines were treated in triplicates with
PLX4032 and parallel vehicle control in the given concen-
trations for 120 hours. Viable cells was measured using a
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium (MTS)-based colorimetric cell proliferation assay
(Promega, Madison, WI). Cell line doubling time were
determined from cell numbers measured in duplicates
every 24 hours for a period of 9 to 12 days using a Vi-
CELL series cell viability analyzer (Beckman Coulter).
The doubling time in 24 hours was calculated by the for-
mula 1/{[((logC2)-(logC1))×3.32]/T}, where C1 = the ini-
tial cell number, C2 = the final cell number, and T = 24
hours. The average of day 3, 4, 5 was used as the optimal
doubling time for the given experimental condition.
Phosphoflow staining
Cells were plated and treated with 1 μM PLX4032 or
vehicle control for 1 or 20 hours, fixed in 1.6% paraform-
aldehyde (Electron Microscopy Sciences, Hatfield, PA),
permeabilized in 4°C 100% methanol (Fisher Scientific)
and stained with Alexafluor 647-conjugated human anti-
phospho-Erk1/2 (T202/Y204, BD Biosciences, San Jose,
CA) in sterile PBS (Mediatech Inc.) containing 0.5% albu-
min bovine serum and 0.01% sodium azide (both from
Sigma-Aldrich, St. Louis, MO). Flow cytometry was per-
formed on FACSCalibur or FACScan (BD Biosciences)
and data was analyzed using FlowJo (Tree Star Inc,
Asland, OR).
Cell cycle analysis
Cells were treated with 1 μM PLX4032 and parallel vehi-
cle control for 20 to 120 hours, fixed in 70% ethanol
(Pharmco-Aaper, Shelbyville, KY), and then resuspended
in sterile PBS containing 0.5% albumin bovine serum, 180
μL/ml propidium iodide staining solution (BD Biosci-
ences) and 50 μg/mL ribonuclease A from bovine pan-
creas (Sigma-Aldrich). Flow cytometry was performed on
FACSCalibur or FACScan and data was analyzed using
FlowJo.
Apoptosis analysis
Melanoma cell lines were treated with increasing concen-
trations of PLX4032, DMSO vehicle control, or 1 μM of
staurosporine as a positive control, for 120 hours. Cells
were trypsinized and transferred to FACS tubes and
stained with Annexin V-FITC and propidium iodide fol-Søndergaard et al. Journal of Translational Medicine 2010, 8:39
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lowing the manufacturer's instructions (BD Biosciences)
and analyzed by flow cytometry using FACSCalibur as
described [13].
Western Blotting
Western blotting was performed as previously described
[14]. Primary antibodies included p-Akt Ser473 and
Thr308, Akt, p-S6K, S6K, p-S6 Ser235/236, S6, PTEN, p-
ERK Thr204/205, ERK, p-AMPK, AMPK (all from Cell
Signaling Technology, Danvers, MA), and α-actin (Sigma-
Aldrich). The immunoreactivity was revealed by use of an
ECL kit (Amersham Biosciences Co, Piscataway, NJ).
In vitro metabolic tracer uptake assay
104  cells/well were plated on 0.001% poly-L-lysine
(Sigma-Aldrich) pre-incubated filter bottom 96-well
plates (multiscreen HTS GV 0.22 μm opaque, Millipore,
Billerica, MA) and rested for 24 hours. 1 μM PLX4032
and parallel vehicle control were added in triplicates for
20 hours. Cells were incubated for 1 hour with 0.5 μCi
with one of the three metabolic tracers with analogues
used as PET tracers: 2-FDG [5,6-3H] (American Radiola-
beled Chemicals Inc., St. Louis, MO) in glucose-free
DMEM (Invitrogen), or 2'-Deoxy-2'-fluoroarabinofura-
nosylcytosine-[3H], and thymidine [methyl-3H] (FAC and
thymidine, Moravek Biochemicals Inc., Brea, CA) in
RPMI 1640. Extracellular metabolic tracer was washed
off using a multiscreen HTS vacuum manifold system
(Millipore). 100 μL scintillation fluid (Perkin Elmer,
Waltham, MA) was added to each well and tritium count
was measured on a 1450 microbeta trilux microplate
(Perkin Elmer).
In vivo microCT and microPET studies
Mice with established subcutaneous human melanoma
xenografts were treated for 3 days with 100 mg/kg
PLX4032 in corn oil or vehicle control twice daily by oral
gavage. The last treatment was given one hour prior to
intraperitoneal injection of 200 μCi [18F]-FDG, which was
allowed to distribute in the tissues for 1 hour before
microPET scanning as previously described [15].
Statistical analysis
Continuous variables were compared using a paired Stu-
dent's t-test with two-tailed P values.
Results
PLX4032 specifically blocks the MAPK pathway in 
melanoma cell lines with the BRAFV600E mutation
We tested the ability of PLX4032 to differentially block
MAPK pathway signaling in a panel of human melanoma
cell lines (Table 1) by quantitating the inhibition of phos-
phorylated Erk (pErk), a downstream target of B-Raf
activity, using intracellular phosphospecific flow cytome-
try (Figure 1A). As expected, cell lines with BRAFV600E
mutation had a fast (detectable at 1 hour) and sustained
(persistent at 20 hours, Figure 1B) inhibition of pErk,
although one of the cell lines (M263) had lower inhibition
of pErk than the rest. There was no pErk inhibition in two
cell lines with NRAS Q61L mutation (M202 and M207)
and a cell line wild type for both oncogenes (M257). In
fact, there was a markedly increased pErk signal in one
NRAS  Q61L mutated cell line (M207), an observation
consistent with data from others that has been attributed
t o  l o s s  o f  n e g a t i v e  r e g u l a t o r y  p a t h w a y s  [ 1 6 , 1 7 ]  a n d
enhanced signaling through C-Raf [18,19]. Therefore,
PLX4032 inhibits MAPK pathway signaling specifically in
cell lines that harbor the BRAFV600E mutation.
Differential sensitivity to PLX4032 in BRAFV600E mutated 
melanoma cell lines
Melanoma cell lines with different NRAS/BRAF  muta-
tional status were treated in vitro with a range of concen-
trations of PLX4032 for 5 days. The three cell lines
without BRAFV600E mutation were resistant to PLX4032.
Seven  BRAFV600E  mutant cell lines were sensitive to
PLX4032, including four highly sensitive cell lines with
half maximal inhibitory concentration (IC50) values
below 1 μM. Surprisingly, in three cell lines with
BRAFV600E mutation we could not determine an IC50 with
increasing concentrations of PLX4032 up to 10 μM, sug-
gesting that these cell lines are resistant to this agent in a
5-day exposure in vitro (Figure 1C). Similar results have
been obtained in 3-day viability assays and when
PLX4032 is added daily to the cultures or just at the
beginning of the experiment (data not shown).
PLX4032 has similar inhibitory effects on cell cycle in 
sensitive and resistant BRAFV600E mutant cell lines
To study effects of PLX4032 on cell cycle progression
downstream of B-Raf signaling we used propidium iodide
flow cytometric staining. As expected, PLX4032 had no
effect on cell cycle progression in melanoma cell lines
without a BRAFV600E mutation (Figure 2A). In contrast,
PLX4032 exposure for one (data not shown) or 20 hours
(Figure 2B and 2C) led to a similar and profound G1
arrest in all BRAFV600E mutant cell lines regardless of their
in vitro sensitivity to PLX4032.
PLX4032 leads to apoptotic death in sensitive BRAFV600E 
but not in resistant BRAFV600E mutated melanoma cell lines
We then analyzed the ability of PLX4032 to differentially
induce apoptotic effects against melanoma cell lines with
the BRAFV600E mutation. Using a BRAFV600E mutant mela-
noma cell line with a good response to PLX4032 (M249)
and another one that was poorly responsive to PLX4032
(M233) based on cell viability assays, we analyzed apop-
totic induction using flow cytometry based on the incor-
poration of propidium iodide and Annexin V. AfterSøndergaard et al. Journal of Translational Medicine 2010, 8:39
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Table 1: Genomic characterization, growth kinetics and sensitivity towards PLX4032 for a panel of human melanoma cell 
lines.
Cell Line NRAS/BRAF Number of BRAF 
Gene Copies
Other Oncogenic Events Cell line 
doubling time 
(hours)
PLX4032 IC50 (μM)
M257 Wild type 3 CDKN2A R80 31.4 Not reached
M202 NRAS Q61L 2 EGFR amplification
CDKN2A homozygous deletion
26.1 Not reached
M207 NRAS Q61L 2 MITF amplification
PTEN heterozygous deletion
25.2 Not reached
M233 BRAFV600E 
Heterozygous
3 AKT1 amplification
CCND1 amplification
EGFR amplification
CDKN2A homozygous deletion
PTEN homozygous deletion
29.6 Not reached
M255 BRAFV600E 
Heterozygous
2 AKT2 amplification
CCND1 amplification
EGFR amplification
CDKN2A homozygous deletion
48.6 Not reached
M308 BRAFV600E 
Heterozygous
3 MITF amplification
AKT2 amplification
EGFR amplification
CDKN2A heterozygous deletion
35.0 Not reached
M263 BRAFV600E 
Heterozygous
2 CDKN2A heterozygous deletion 23.3 10
M321 BRAFV600E 
Homozygous
23 4 . 1 7 . 5
SKMEL28 BRAFV600E 
Homozygous
2 EGFR P753S
MITF amplification
CCND1 amplification
CDKN2A heterozygous deletion
PTEN heterozygous deletion
26.9 4.6
M229 BRAFV600E 
Homozygous
4 MITF amplification
AKT1 amplification
PTEN heterozygous deletion
27.9 0.2
M238 BRAFV600E 
Heterozygous
2 CDKN2A homozygous deletion
PTEN heterozygous deletion
28.1 0.7
M249 BRAFV600E 
Heterozygous
3 MITF amplification
AKT2 amplification
PTEN homozygous deletion
21.2 0.8
M262 BRAFV600E 
Homozygous
2 AKT1 E17K
AKT1 amplification
EGFR amplification
CDKN2A homozygous deletion
47.4 0.1Søndergaard et al. Journal of Translational Medicine 2010, 8:39
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PLX4032-treatment, the increase in Annexin V positive
cells, with or without being double positive for propidium
iodide, was greater in the PLX4032-responsive M249
cells compared to the poorly responding M233 cells (Fig-
ure 2D and 2E). Similar results were obtained with M238
and M263 (data not shown). Taken together with the data
on cell cycle inhibition, these data suggest that PLX4032
has cytostatic effects in BRAFV600E mutant cell lines with
a poor response, while it has cytostatic and cytotoxic
effects in cell lines with a good response to PLX4032 in
cell viability assays.
Functional and genomic characterization of BRAFV600E 
mutated cell lines with different sensitivity to PLX4032
We tested if the differences in sensitivity to PLX4032
were due to markedly different doubling times. Resistant
BRAFV600E mutated cell lines tended to have a slower dou-
bling time compared to the sensitive BRAFV600E mutated
cell lines (P = 0.24, Table 1). The lack of significance was
due to outliers in a small group, most notably the highly
sensitive cell line M262 having a doubling time close to 50
hours. Interestingly, all cell lines homozygous for the
BRAFV600E mutation were moderately to highly sensitive
to PLX4032, and cell lines resistant to PLX4032 were all
heterozygous for BRAFV600E (P = 0.16). However, there
were also two highly sensitive heterozygous cell lines with
IC50 values below 1 μM of PLX4032, and the sensitivity of
homozygous cell lines spreads through one-log differ-
ences in PLX4032 concentrations (Table 1). We then used
high throughput analysis of over 500 gene mutations
using mass-spectrometry based genotyping [11] and
high-density SNP arrays to explore other genomic altera-
tions. Two different platforms (Illumina and Affymetrix)
gave highly concordant results (data not shown) demon-
strating that out of the 10 cell lines with BRAFV600E muta-
tion, four have amplification of the BRAF locus (Table 1).
There was no clear relationship between these amplifica-
tion events and the BRAFV600E zygosity or the sensitivity
to PLX4032. There were very few secondary mutations in
this group of cell lines, with one cell line having a muta-
tion in EGFR, and one cell line with a mutation in AKT
(Table 1). In addition, the M257 cell line, which is wild
type for both NRAS and BRAF and is highly resistant to
PLX4032, was found to have 3 copies of wild type BRAF
and a point mutation in CDKN2A. The distribution of
amplification events in MITF and EGFR were also spread
among the cell lines. Of note, there was no clear trend
regarding the activation of the PI3K/Akt pathway based
on activating mutations, or amplifications of AKT1/2 seg-
regating the resistant and sensitive cell lines. Supervised
hierarchical clustering comparing SNP array data from
PLX4032-resistant and -sensitive BRAFV600E mutant cell
lines did not point to specific genomic areas with concor-
dant alterations differentiating the two groups of cell
lines.
Modulation of MAPK and PI3k/Akt signaling pathways in 
sensitive and resistant cell lines
To further explore how cell lines with BRAFV600E muta-
tion respond differently to PLX4032 we chose two
extreme examples of cell lines with similar growth kinet-
ics to perform an extended analysis of signaling pathways
(Figure 3). M229 is one of the two most sensitive cell
lines, while M233 proved to be very resistant despite hav-
ing a short in vitro doubling time (Table 1). Exposure to
PLX4032 resulted in a marked decrease in pErk in both
cell lines, but this was more prominent and durable in the
sensitive M229 compared to the resistant M233. M229
has a heterozygous PTEN deletion by SNP array analysis,
and had a detectable band for PTEN protein by Western
blot that did not change with PLX4032 exposure. The
resistant M233 cell line has a homozygous PTEN deletion
and has no PTEN protein by Western blot. This corre-
lates with baseline pAkt detectable in M233 but not
M229, as well as increase in pAkt upon PLX4032-expo-
sure in the resistant M233 but not in the sensitive M229
cell line. Interestingly, pS6 decreased in both cell lines
upon PLX4032 exposure. Finally, we explored if there was
modulation of AMPK, which has been recently described
as a downstream modulator of glucose metabolism in
BRAFV600E mutants [20]. There was a low level of induc-
tion of pAMPK. These studies demonstrate that PLX4032
has complex effects on MAPK and PI3k/Akt signaling
pathways that may be dependent on secondary oncogenic
events beyond B-Raf.
Non-invasive imaging of PLX4032 anti-tumor activity
We analyzed the uptake profile of three different meta-
bolic tracers that can be used in PET scans: two nucleo-
side analogs (thymidine and FAC [21]) and FDG, a
glucose analog widely used as a PET tracer. As expected,
BRAF wild type cell lines had no significant change in
uptake of thymidine or FAC upon PLX4032-exposure.
Conversely, all BRAFV600E mutated cell lines, irrespective
of their sensitivity to PLX4032, had markedly decreased
uptake of these two nucleoside analogues (Figure 4a and
4b). The greatest difference between PLX4032-sensitive
and -resistant BRAFV600E mutants was in FDG uptake.
The percentage decrease in FDG uptake was roughly
double in PLX4032-sensitive BRAFV600E mutants com-
pared to PLX4032-resistant cell lines (P = 0.009, Figure
4c). Finally, we tested if [18F]-FDG uptake could be used
as a pharmacodynamic marker of B-RafV600E inhibition by
PLX4032  in vivo. Mice with established subcutaneous
M249 melanoma xenografts, a cell line highly sensitive to
PLX4032 in vitro, were treated for 3 days with PLX4032
twice daily by oral gavage, and then analyzed by com-Søndergaard et al. Journal of Translational Medicine 2010, 8:39
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Figure 1 PLX4032 modulation of the MAPK pathway and melanoma cell line viability. Melanoma cell lines treated with 1 μM PLX4032 for 20 
hours were stained with pErk antibody and analyzed by flow cytometry. a) Representative flow cytometry histogram showing the fluorescence inten-
sity of pErk in cells treated with vehicle control or PLX4032. b) Comparison of percentage change in pErk for a panel of 10 melanoma cell lines with 
different NRAS/BRAF mutational status. c) In vitro cell viability upon culture with increasing concentrations of PLX4032 (from 0.001-10 μM) for 120 hours. 
Cell viability was determined using an MTS-based assay.
c)
a)
Unstained Vehicle/medium
PLX4032 (80.1% decrease)
M238
WT
NRAS Q61L
BRAF V600E heterozygous
BRAF V600E homozygous
b)Søndergaard et al. Journal of Translational Medicine 2010, 8:39
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Figure 2 Effects of PLX4032 on cell cycle and apoptosis. a-c) Melanoma cell lines were cultured with 1 μM of PLX4032 for 20 hours and stained 
with propidium iodide for cell cycle analysis gated on live cells. a) NRAS Q61L mutants, b) BRAFV600E mutants resistant to PLX4032, c) BRAFV600E mutants 
sensitive to PLX4032. d-e) Melanoma cell lines were cultured with 1 μM of PLX4032, vehicle control, or 1 μM of staurosporine (SSP - positive control 
to induce apoptosis) for 120 hours and analyzed by flow cytometry for apoptotic cell death upon double-staining with Annexin V and propidium io-
dide. Testing included a PLX4032-resistant cell line (M233) and a highly sensitive cell line (M249), both of which are BRAFV600E mutants.
0 200 400 600 800 100
FL2- A
0
20
40
60
80
100
%
 
o
f
 
M
a
x
M20
M202
0 200 400 600 800100
FL2- A
0
20
40
60
80
100
%
 
o
f
 
M
a
x
0
M20
M207
0 200 400 600 800 10
FL2- A
0
20
40
60
80
100
%
 
o
f
 
M
a
x
M2
M229
0 200 400 600 800 10
FL2- A
0
20
40
60
80
100
%
 
o
f
 
M
a
x
M2
M249
Vehicle control
PLX4032 1 µM
a)
b)
c)
0 200 400 600 800100
FL2- A
0
20
40
60
80
100
%
 
o
f
 
M
a
x
0
M23
M233
0 200 400 600 800 100
FL2- A
0
20
40
60
80
100
%
 
o
f
 
M
a
x
M26
M263
Medium Vehicle control  PLX4032 1 µM  SSP
M233
P
.
I
.
Annexin V
d)
e)
P
.
I
.
M249
G1
G2/M
G1
G2/M
G2/M
G2/M
G2/M G2/M
G1 G1
G1 G1Søndergaard et al. Journal of Translational Medicine 2010, 8:39
http://www.translational-medicine.com/content/8/1/39
Page 8 of 11
bined microPET and microCT using [18F]-FDG as PET
tracer. There was a 32% decrease in [18F]-FDG uptake
compared to the vehicle control mice, even though tumor
sizes were not different at this early time point (Figure
4d). In conclusion, inhibition of [18F]-FDG uptake can be
used as an early marker of effective B-RafV600E inhibition
by PLX4032.
Discussion
The  BRAFV600E mutation is one of the most common
kinase domain mutations in human cancer with a partic-
ularly high incidence in malignant melanoma [3,7]. The
Raf-inhibitors PLX4720 and PLX4032 have the preclini-
cal characteristics of functioning as specific inhibitors of
the  BRAFV600E mutated kinase with a favorable profile
compared to wild type kinases [9,22]. Understanding the
patterns of sensitivity and resistance in melanomas with
different oncogenic events is of high importance for clini-
cal translation. Our studies confirmed the high specificity
of PLX4032 for a subset of BRAFV600E mutant cell lines
[22]. Surprisingly, we noted differences in the sensitivity
to PLX4032, with some BRAFV600E mutants demonstrat-
ing resistance to the cytotoxic effects of PLX4032. In
most cases, these cells had a tendency towards slower
growth kinetics and being heterozygous for BRAFV600E.
This differential response to PLX4032 in BRAFV600E
mutant melanoma cell lines may be explained by several
mechanisms. It may be that there is preferential MAPK
pathway-addiction in sensitive cell lines, and cells with
lower sensitivity are less dependent on the BRAFV600E
oncogenic signaling, relying on the co-activation of other
signaling pathways including the PI3K/Akt pathway. We
explored this possibility with SNP arrays and high
throughput oncogene sequencing with a particular inter-
est in looking at this pathway. The genomic analysis
revealed that alterations in PI3K/Akt, including deletions
of PTEN, amplifications of AKT and activating mutations
in AKT were distributed throughout the cell line list with
Figure 3 Western blot analysis of phosphorylated and total amount of key proteins in the MAPK and PI3k/Akt pathways. a) The PLX4032-
sensitive M229 cell line and the PLX4032-resistant M233 cell line were cultured in different concentrations of PLX4032 for 24 hours and lysates were 
analyzed by Western blot. b) M229 and M233 cells were treated by PLX4032 in a time course over 24 hours, and cell lysates were analyzed by Western 
blot.
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Figure 4 Metabolic tracer uptake profile upon exposure to PLX4032. a-c) in vitro PET tracer uptake profiles for 11 different melanoma cell lines. 
Tritium counts was measured on a micro-beta reader and PLX4032 treated cells were compared to vehicle control and relative PET tracer uptake cal-
culated. a) [3H]-thymidine uptake profile, b) [3H]-FAC uptake profile, c) [3H]-FDG uptake profile. The black lines and the number next to them represent 
the average change in PET tracer uptake of the cell lines with the same mutational status and sensitivity towards PLX4032. d) [18F]FDG PET tracer up-
take in vivo. SCID/beige mice with 5-7 mm M249 melanoma xenografts on the left lower flank were treated twice daily with 100 mg/kg of PLX4032 or 
vehicle control by oral gavage. Three days later mice were imaged by microPET scanning upon administration of [18F]-FDG.Søndergaard et al. Journal of Translational Medicine 2010, 8:39
http://www.translational-medicine.com/content/8/1/39
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no clear pattern of correlation with sensitivity or resis-
tance to PLX4032. However, in two cell lines phospho-
specific Western blot staining suggested that the resistant
cell line had increased Akt signaling upon PLX4032 expo-
sure. Another possibility is that PLX4032-resistant
BRAFV600E mutants have alternative signaling at the level
of Raf, as has been described for cell lines with acquired
resistance to a different Raf-inhibitor, AZ628, which show
increased signaling through C-Raf [23]. The increase in
pErk in an NRAS  Q61L mutant cell line could be
explained by abrogation of negative feedback loops medi-
ated mainly by dual specificity phosphatases (MKPs/
DUSPs), as reported with Mek inhibitors [17,24], and the
recent description of increased C-Raf signaling when het-
erodimerizing with inhibited B-Raf in BRAF  wild type
cells [18,19]. Therefore, the modulation of feed-back
loops and alteration of Raf dimerization upon treatment
with Raf inhibitors may also have a role in the differential
sensitivity to PLX4032 in BRAFV600E mutant cell lines.
Finally, differences in expression of pro- and anti-apop-
totic molecules like Bim and Bad [25] may allow some
BRAFV600E mutant cell lines to undergo growth arrest but
not die from apoptosis upon exposure to PLX4032. Stud-
ies are ongoing to further explore these possibilities.
We explored the use of PET imaging as a mean to non-
invasively detect PLX4032-sensitivity. In vitro we found
that any of the three PET tracers FDG, FLT and FAC
could be used to distinguish between melanomas with a
NRAS or a BRAFV600E mutation based on the differential
effects of PLX4032 on cell cycle and metabolism. FDG
could furthermore be used to distinguish between
BRAFV600E mutant melanomas with high or low sensitiv-
ity to PLX4032. The PI3K/Akt pathway has been widely
r e g a r d e d  a s  h a v i n g  a  r o l e  i n  t h e  r e g u l a t i o n  o f  g l u c o s e
metabolism through mTOR, but recently the LKB1-
AMPK pathway has been found to be regulated by onco-
genic  BRAFV600E  signaling [20], which together may
explain the marked and rapid effects of PLX4032 on
inhibiting FDG uptake. We explored this possibility in
two cell lines. Our data suggests a minor increase in
pAMPK upon PLX4032 exposure, which may be in line
with the proposed hypothesis [20].
Conclusions
These studies in melanoma cell lines may allow to better
interpret the results of a recently reported phase I clinical
trial with PLX4032 [26], with an objective response in
excess of 70% of patients with BRAFV600E positive meta-
static melanoma. The characterization of PLX4032-sensi-
tive and -resistant BRAFV600E mutant melanoma cell lines
may provide information about the molecular mecha-
nisms that dictate sensitivity and resistance to PLX4032.
In addition, molecular imaging with [18F]FDG PET scans
may help in providing an early readout of complete or
incomplete pharmacodynamic effects of PLX4032 and
therefore predict lesions that may or may not respond to
therapy.
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